Modificare „Graybug Vision, Inc.”

Pagina dedicata companiei Graybug Vision, Inc. listata cu simbolul US.GRAY

==Descriere companie==
Graybug Vision, Inc.(www.graybug.com) is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The Company's lead product candidate, GB-102, is an intravitreal injection of a microparticle depot formulation of sunitinib, an inhibitor of neovascular growth and permeability, which are causes of retinal disease. It is developing GB-102 as a once-every-six months intravitreal injection for the treatment of wet age-related macular degeneration or wet (AMD) and diabetic macular edema (DME). It is also using its technologies to develop GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy (DR), as well as GB-401, an intravitreally injectable depot formulation of a beta-adrenergic blocking agent prodrug with a dosing regimen of once every six months or longer for the treatment of primary open-angle glaucoma (POAG).

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.GRAY" />

==Ultimele stiri despre Graybug Vision, Inc. (US.GRAY)==
<dynamicpagelist>
category=US.GRAY
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.GRAY]][[Categorie:Stiri despre companii]]